Key Points
- CEO Daniel Antonio Perez sold 166,665 Hinge Health shares on Feb. 12 at an average price of $40.26 for $6.71 million, and he also sold similar blocks on Jan. 5 and Dec. 15 at higher prices, indicating a pattern of insider selling.
- The board approved a $250 million share repurchase plan (about 7.2% of shares), while the stock recently traded around $38.91 with a 12‑month range of $30.08–$62.18 and a market cap of roughly $3.06 billion.
- Analysts and institutions show support: the consensus rating is "Moderate Buy" with a $57.71 target, several firms have buy/overweight ratings, and large investors like BIT Capital and Vanguard materially increased their stakes.
Hinge Health Inc. (NYSE:HNGE - Get Free Report) CEO Daniel Antonio Perez sold 166,665 shares of the business's stock in a transaction that occurred on Thursday, February 12th. The stock was sold at an average price of $40.26, for a total value of $6,709,932.90. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
Daniel Antonio Perez also recently made the following trade(s):
- On Monday, January 5th, Daniel Antonio Perez sold 166,665 shares of Hinge Health stock. The stock was sold at an average price of $46.38, for a total transaction of $7,729,922.70.
- On Monday, December 15th, Daniel Antonio Perez sold 166,670 shares of Hinge Health stock. The shares were sold at an average price of $48.53, for a total transaction of $8,088,495.10.
Hinge Health Trading Down 1.4%
NYSE:HNGE opened at $38.91 on Friday. Hinge Health Inc. has a twelve month low of $30.08 and a twelve month high of $62.18. The company has a market cap of $3.06 billion and a P/E ratio of -2.97. The company's 50-day moving average price is $43.53 and its 200-day moving average price is $48.75.
Hinge Health announced that its board has initiated a share repurchase plan on Wednesday, November 12th that authorizes the company to repurchase $250.00 million in shares. This repurchase authorization authorizes the company to purchase up to 7.2% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company's board of directors believes its shares are undervalued.
Analyst Ratings Changes
HNGE has been the topic of a number of recent research reports. Freedom Capital raised Hinge Health to a "strong-buy" rating in a research note on Thursday, January 22nd. Canaccord Genuity Group lowered their price target on shares of Hinge Health from $65.00 to $53.00 and set a "buy" rating on the stock in a research report on Wednesday. Piper Sandler cut their price objective on shares of Hinge Health from $71.00 to $60.00 and set an "overweight" rating for the company in a research report on Friday, January 9th. Wells Fargo & Company initiated coverage on shares of Hinge Health in a report on Thursday, January 8th. They issued an "overweight" rating and a $68.00 target price on the stock. Finally, Evercore ISI set a $50.00 price target on shares of Hinge Health and gave the company an "outperform" rating in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $57.71.
Read Our Latest Report on Hinge Health
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of the stock. BIT Capital GmbH grew its stake in Hinge Health by 79.3% during the 4th quarter. BIT Capital GmbH now owns 3,316,101 shares of the company's stock worth $154,033,000 after purchasing an additional 1,466,577 shares in the last quarter. Vanguard Group Inc. raised its position in Hinge Health by 110.5% in the 4th quarter. Vanguard Group Inc. now owns 2,605,532 shares of the company's stock valued at $121,027,000 after purchasing an additional 1,367,693 shares in the last quarter. Marshall Wace LLP purchased a new position in shares of Hinge Health in the 4th quarter valued at about $54,469,000. Bamco Inc. NY acquired a new position in shares of Hinge Health during the second quarter worth about $48,943,000. Finally, Braidwell LP purchased a new stake in shares of Hinge Health during the third quarter worth approximately $44,686,000.
About Hinge Health
(
Get Free Report)
Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company's platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.
Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
